These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 33365294)

  • 21. Cross-sectional Study on the Impact of Discount Pricing and Price Competition on Community Pharmacy Practice.
    Mathews A; Ming LC; Che Rose FZ; Abbas SA
    Cureus; 2020 Aug; 12(8):e9903. PubMed ID: 32839684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons from game theory about healthcare system price inflation: evidence from a community-level case study.
    Agee MD; Gates Z
    Appl Health Econ Health Policy; 2013 Feb; 11(1):45-51. PubMed ID: 23329381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
    Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
    Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
    Naidoo K; Suleman F
    S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia's private healthcare sector.
    Ahmad NS; Hatah E; Makmor-Bakry M
    J Pharm Policy Pract; 2019; 12():15. PubMed ID: 31304021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reimbursement of generics in Croatia: should more have been done?].
    Vukusić M
    Lijec Vjesn; 2010; 132(5-6):134-43. PubMed ID: 20677618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prices Paid to Hospitals by Private Health Plans Are High Relative to Medicare and Vary Widely: Findings from an Employer-Led Transparency Initiative.
    White C; Whaley CM
    Rand Health Q; 2021 Aug; 9(2):5. PubMed ID: 34484877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
    Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
    PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
    Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
    Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.